Evidence map›Paper›PMID 37047065›Full record

SynthesisInternational journal of molecular sciences2023

Circulating Pulmonary-Originated Epithelial Biomarkers for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.

Huishu Lin, Qisijing Liu, Lei Zhao, Ziquan Liu, Huanhuan Cui, Penghui Li, Haojun Fan, Liqiong Guo

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07774338 (Early Admission Serum Soluble Receptor for Advanced Glycation End Products), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07774338 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Early Admission Serum Soluble Receptor for Advanced Glycation End Products (sRAGE), Club Cell Protein-16 (CC16), and Syndecan-1 as Independent Predictors of Acute Respiratory Distress Syndrome and In-Hospital Mortality Following Severe Isolated Chest Trauma: A Prospective Cohort Study.

TypeobservationalSponsorAssiut UniversityRan2026 to 2028Enrolled85ConditionsAcute Respiratory Distress Syndrome, Chest TraumaArmsNo intervention - observational study
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Observational
  6. Article
  7. Review
  8. LIPS and PaOMediators of inflammation · 2024
    Observational
  9. Medicina (Kaunas, Lithuania) · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huishu LinInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China.
Qisijing LiuResearch Institute of Public Health, School of Medicine, Nankai University, Tianjin 300381, China.
Lei ZhaoInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China.
Ziquan LiuInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China.
Huanhuan CuiWenzhou Safety (Emergency) Institute, Tianjin University, Wenzhou 325000, China.
Penghui LiSchool of Environmental Science and Safety Engineering, Tianjin University of Technology, Tianjin 300384, China.
Haojun FanInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China.
Liqiong GuoInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China.ORCID 0000-0002-1141-9646

Funding

Fundamental Research Funds for the Central Universities, Nankai University 63221058The Scientific Research Translational Foundation of Wenzhou Safety (Emergency) Institute of Tianjin University TJUWYY2022002The Scientific Research Translational Foundation of Wenzhou Safety (Emergency) Institute of Tianjin University TJUWYY2022019Tianjin Research Innovation Project for Postgraduate Students 2021YJSB193
6 · The paper itself

Abstract

Previous studies have found several biomarkers for acute respiratory distress syndrome (ARDS), but the accuracy of most biomarkers is still in doubt due to the occurrence of other comorbidities. In this systematic review and meta-analysis, we aimed to explore ideal ARDS biomarkers which can reflect pathophysiology features precisely and better identify at-risk patients and predict mortality. Web of Science, PubMed, Embase, OVID, and the Cochrane Library were systematically searched for studies assessing the reliability of pulmonary-originated epithelial proteins in ARDS. A total of 32 studies appeared eligible for meta-analysis, including 2654 ARDS/ALI patients in this study. In the at-risk patients' identification group, the highest pooled effect size was observed in Krebs von den Lungren-6 (KL-6) (SMD: 1.17 [95% CI: 0.55, 1.79]), followed by club cell proteins 16 (CC16) (SMD: 0.74 [95% CI: 0.01, 1.46]), and surfactant proteins-D (SP-D) (SMD: 0.71 [95% CI: 0.57, 0.84]). For the mortality prediction group, CC16 exhibited the largest effect size with SMD of 0.92 (95% CI: 0.42, 1.43). Meanwhile, the summary receiver operating characteristic (SROC) of CC16 for ARDS diagnosis reached an AUC of 0.80 (95% CI: 0.76, 0.83). In conclusion, this study provides a ranking system for pulmonary-originated epithelial biomarkers according to their association with distinguishing at-risk patients and predicting mortality. In addition, the study provides evidence for the advantage of biomarkers over traditional diagnostic criteria. The performance of biomarkers may help to clinically improve the ARDS diagnosis and mortality prediction.

Indexed as

LungRespiratory Distress SyndromeBiomarkersHumansReproducibility of ResultsROC CurveBiomarkersacute lung injuryacute respiratory distress syndromebiomarkerpulmonary-originated proteins

Identifiers

PMID37047065
PMCPMC10093822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.